Low-dose metronomic doxorubicin inhibits mobilization and differentiation of endothelial progenitor cells through REDD1-mediated VEGFR-2 downregulation |
Park, Minsik
(Department of Molecular and Cellular Biochemistry, Kangwon National University School of Medicine)
Kim, Ji Yoon (Department of Anaesthesiology and Pain Medicine, Hanyang University Hospital) Kim, Joohwan (Department of Molecular and Cellular Biochemistry, Kangwon National University School of Medicine) Lee, Jeong-Hyung (Department of Biochemistry, Kangwon National University) Kwon, Young-Guen (Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University) Kim, Young-Myeong (Department of Molecular and Cellular Biochemistry, Kangwon National University School of Medicine) |
1 | Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2, 1097-1105 DOI |
2 | Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399-403 DOI |
3 | Kim JY and Kim YM (2019) Tumor endothelial cells as a potential target of metronomic chemotherapy. Arch Pharm Res 42, 1-13 DOI |
4 | Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358, 2039-2049 DOI |
5 | Karar J and Maity A (2011) PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4, 51 DOI |
6 | Marumo T, Uchimura H, Hayashi M, Hishikawa K and Fujita T (2006) Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 48, 490-496 DOI |
7 | Lee DK, Kim JH, Kim J et al (2018) REDD-1 aggravates endotoxin-induced inflammation via atypical NF-κB activation. FASEB J 32, 4585-4599 DOI |
8 | Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T and Peters SO (2008) Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 22, 831-836 |
9 | Kerbel RS and Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436 DOI |
10 | Rasanen M, Degerman J, Nissinen TA et al (2016) VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 113, 13144-13149 DOI |
11 | Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-135 DOI |
12 | Wang M, Xu Y, Wen GZ, Wang Q and Yuan SM (2019) Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression. Onco Targets Ther 12, 4643-4654 DOI |
13 | Pitchford SC, Furze RC, Jones CP, Wengner AM and Rankin SM (2009) Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4, 62-72 DOI |
14 | Aicher A, Heeschen C, Mildner-Rihm C et al (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9, 1370-1376 DOI |
15 | Giraud S, Greco A, Brink M, Diaz JJ and Delafontaine P (2001) Translation initiation of the insulin-like growth factor I receptor mRNA is mediated by an internal ribosome entry site. J Biol Chem 276, 5668-5675 DOI |
16 | Bocci G, Francia G, Man S, Lawler J and Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100, 12917-12922 DOI |
17 | Saif MW (2013) Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res 5, 103-115 DOI |
18 | Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147 DOI |
19 | Murakami J, Li TS, Ueda K, Tanaka T and Hamano K (2009) Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int J Cancer 12, 1685-1692 |
20 | Sxton RA and Sabatini DM (2017) mTOR Signaling in growth, metabolism, and disease. Cell 169, 361-371 |
21 | Chen TG, Chen JZ and Wang XX (2006) Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 39, 117-125 DOI |
22 | DeYoung MP, Horak P, Sofer A, Sgroi D and Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22, 239-251 DOI |
23 | Park M, Kim J, Kim T et al (2021) REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3. Exp Mol Med (In press) |
24 | Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63, 4342-4346 |
25 | Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 DOI |
26 | Asahara T, Masuda H, Takahashi T et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85, 221-228 DOI |